Area of research
Rheumatology · Pathology and Forensic Medicine
Research interest
Research interests include Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments, Multiple Sclerosis Research Studies, and Genetic Associations and Epidemiology.
Diagnostic accuracy in the Swedish national patient register: a review including diagnoses in the outpatient register
Completeness and generalizability of the Swedish MS register
<scp>COMBAT</scp>‐<scp>MS</scp>: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
The Swedish medical birth register during five decades: documentation of the content and quality of the register
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis
Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application
Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
Generalizability and effect measure modification in sibling comparison studies
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
Sibling Comparison Studies
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden
Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
Validation of the Swedish Multiple Sclerosis Register
Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice
Apgar Score Components at 5 Minutes: Risks and Prediction of Neonatal Mortality
Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry